文献速递血液净化与透析慢性肾脏病

维生素K补充与透析患者骨密度:双盲随机安慰剂对照RenaKvit试验结果

Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

多中心双盲安慰剂对照试验纳入123例维持性透析患者,随机接受MK-7 360 µg/日或安慰剂2年。MK-7组桡骨远端1/3骨密度较安慰剂组加速下降,而安慰剂组腰椎骨密度下降被阻止,其余部位无显著差异。结论不支持用MK-7补充来保护透析患者骨骼。

要点

  • 与安慰剂相比,MK-7 360 µg/日补充2年加速桡骨远端1/3骨密度丢失。
  • MK-7组阻止了安慰剂组观察到的腰椎骨密度下降。
  • 其余骨骼部位骨密度未见显著影响,结论不支持MK-7用于保护透析患者骨骼。

核心结论

  • 与安慰剂相比,MK-7补充2年加速桡骨远端1/3骨密度丢失,但阻止了腰椎骨密度下降。
  • MK-7补充可能部位特异性地改变透析患者骨密度,总体结果不支持用MK-7补充来保护透析患者骨骼。

研究设计与样本

  • 多中心、双盲、安慰剂对照干预试验。
  • 123例维持性透析患者随机接受每日口服MK-7 360 µg或安慰剂,持续2年。
  • 采用双能量X射线吸收法评估桡骨远端(1/3、中段、超远端和总体)、股骨颈、腰椎(L1-L4)和全身骨密度。
  • 检测血清维生素K1和MK-7水平及血浆总骨钙素、去磷酸化未羧化基质Gla蛋白和维生素K缺乏诱导蛋白II水平以评估维生素K状态。

主要发现

  • 2年后,MK-7组桡骨远端1/3骨密度较安慰剂组加速丢失,变化均值差为-0.023 g/cm2(95%CI -0.039至-0.008)。
  • 安慰剂组腰椎骨密度下降被阻止,组间变化均值差为0.050 g/cm2(95%CI 0.015-0.085)。
  • 其余骨骼部位未观察到显著效应。
  • MK-7补充组维生素K状态强烈改善。

临床怎么用

  • 原文结论为:总体结果不支持用MK-7补充来保护透析患者骨骼。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitamin K deficiency is highly prevalent in patients on dialysis and may contribute to their low bone mineral density (BMD) and increased risk of fracture. This study investigated the effect of menaquinone-7 (MK-7) supplementation on BMD in patients on chronic dialysis. METHODS: In a multicentre, double-blind, placebo-controlled intervention trial, 123 patients on chronic dialysis were randomised to a daily oral supplement of either MK-7 360 µg or placebo for 2 years. BMD of the distal radius (1/3, mid, ultradistal and total), femoral neck, lumbar spine (L1-L4) and whole body was assessed by dual-energy X-ray absorptiometry. Serum levels of vitamin K1 and MK-7 and plasma levels of total osteocalcin, dephosphorylated-uncarboxylated matrix Gla protein and protein induced by vitamin K absence II were measured to assess vitamin K status. RESULTS: After 2 years, an accelerated BMD loss of the 1/3 distal radius was found with MK-7 supplementation {mean difference of changes relative to placebo -0.023 g/cm2 [95% confidence interval (CI) -0.039 to -0.008]}, whereas the decrease in lumbar spine BMD seen in the placebo group was prevented [mean difference of changes between groups 0.050 g/cm2 (95% CI 0.015-0.085)]. No significant effects were observed at the remaining skeletal sites. Vitamin K status strongly improved in MK-7-supplemented participants. CONCLUSION: Compared with placebo, an accelerated BMD loss of the 1/3 distal radius was found after 2 years of MK-7 supplementation, whereas a decline in lumbar spine BMD was prevented. As such, MK-7 supplementation might modify BMD site-specifically in patients on dialysis. In aggregate, our findings do not support MK-7 supplementation to preserve bone in patients on dialysis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Levy-Schousboe K, Marckmann P, Frimodt-Møller M, et al. Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. Nephrol Dial Transplant. 2023. PMID: 36460034. doi:10.1093/ndt/gfac315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。